U35

(2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid

Created:	2021-01-19
Last modified:	2022-03-02

Find Related PDB Entry
3 entries where U35 is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	61
Chiral Atom Count	1
Bond Count	63
Aromatic Bond Count	17

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
Synonyms	Diovan; Tareg; Provas; Exforge; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Systematic Name (OpenEye OEToolkits)	(2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
Formula	C₂₄ H₂₉ N₅ O₃
Molecular Weight	435.519
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3n[nH]nn3)[CH](C(C)C)C(O)=O
SMILES	OpenEye OEToolkits	2.0.7	CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3n[nH]nn3)C(C(C)C)C(=O)O
Canonical SMILES	CACTVS	3.385	CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3n[nH]nn3)[C@@H](C(C)C)C(O)=O
Canonical SMILES	OpenEye OEToolkits	2.0.7	CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3n[nH]nn3)[C@@H](C(C)C)C(=O)O
InChI	InChI	1.03	InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
InChIKey	InChI	1.03	ACWBQPMHZXGDFX-QFIPXVFZSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB00177 ?
Name	Valsartan
Groups	investigational approved
Description	Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [olmesartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.[A174154] By comparison, the angiotensin-converting enzyme inhibitor (ACEI) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibit the conversion of angiotensin I to angiotensin II through inhibition of the ACE enzyme. However, this does not prevent the formation of all angiotensin II within the body. The angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. Valsartan is commonly used for the management of hypertension, heart failure, and Type 2 Diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors. ARBs such as valsartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization.[A174124,A178153,A173869,A185324,A185327,A185333,A185342,A185345] Valsartan also slows the progression of diabetic nephropathy due to its renoprotective effects.[A174157,A174160,A174163] Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed with type 2 diabetes and in nondiabetic patients diagnosed with chronic kidney disease.[A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States.[A174124] Valsartan is generally well-tolerated with a side-effect profile superior to that of other antihypertensive drugs.[A174130,A174133]
Synonyms	N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine Valsartan N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
Brand Names	Valsartan HCTZ Diovan-hct Entresto Sacubitril and Valsartan Byvalson Auro-valsartan HCT Valsartan and Hydrochlorothiazide PMS-valsartan Prexxartan Amlodipine, Valsartan, Hydrochlorothiazide Dafiro HCT Diovan 160mg Tablets Imprida HCT Q-valsartan Hctz Reddy-valsartan Valsartan Teva-valsartan/hctz Amlodipine, Valsartan, and Hydrochlorothiazide Novo-valsartan Diovan Amlodipine, Valsartan and Hydrochlorothiazide Novo-valsartan/hctz Mylan-valsartan M-valsartan Q-valsartan Dafiro Diovan 80mg Tablets Imprida Apo-valsartan/hctz Sandoz Valsartan HCT Taro-valsartan Diovan 80mg Ava-valsartan Copalia Teva-valsartan Amlodipine-valsartan Mylan Neparvis Riva-valsartan Valsartan/htcz Apo-valsartan Diovan HCT AMLODIPINE and VALSARTAN PMS-valsartan-hctz Mylan-valsartan Hctz Valsartan-hctz Valturna Valsartan and hydrochlorothiazide Copalia HCT Sandoz Valsartan Dom-valsartan Exforge Auro-valsartan Diovan 160mg Valsartan HCT Act Valsartan Amlodipine and valsartan Amlodipine and Valsartan Exforge HCT Sacubitril-valsartan Ava-valsartan HCT
Indication	Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (ACEI) is not appropriate.[F4703, L11305] It is also used in combination with [sacubitril].[L36445]
Categories	Agents Acting on the Renin-Angiotensin System Agents causing angioedema Agents causing hyperkalemia Angiotensin 2 Receptor Blocker Angiotensin II Antagonists and Calcium Channel Blockers Angiotensin II Antagonists and Diuretics Angiotensin II receptor antagonists Angiotensin II receptor blockers (ARBs) and calcium channel blockers Angiotensin II receptor blockers (ARBs) and diuretics Angiotensin II receptor blockers (ARBs), plain Angiotensin II Type 1 Receptor Blockers Angiotensin II Type 2 Receptor Blockers Angiotensin Receptor Antagonists Antihypertensive Agents Antihypertensive Agents Indicated for Hypertension Cardiovascular Agents Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Hypotensive Agents OATP1B1/SLCO1B1 Inhibitors OATP1B1/SLCO1B1 Substrates OATP1B3 substrates
ATC-Code	C09DX05 C10BX10 C09DA03 C09CA03 C09DX02 C09DX01 C09DB08 C09DB01 C09DX04
CAS number	137862-53-4

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Type-1 angiotensin II receptor	MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVV...	unknown	antagonist
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate
Solute carrier organic anion transporter family member 1B3	MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKI...	unknown	substrate
Solute carrier organic anion transporter family member 1B1	MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKS...	unknown	substrate,inhibitor
ATP-binding cassette sub-family C member 2	MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLH...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682